Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of a natural hormone in the body that helps to regulate blood sugar levels.
When taken as directed, Ozempic stimulates the release of insulin from the pancreas in response to high blood sugar levels, which helps to lower blood sugar. It also slows down the movement of food from the stomach to the small intestine, reducing the rise in blood sugar levels after meals [1].
Studies have shown that Ozempic significantly reduces hemoglobin A1c (HbA1c), a measure of average blood sugar levels over a period of time, compared to placebo. In a clinical trial, patients taking Ozempic experienced a median reduction in HbA1c of 1.9% compared to a 0.3% reduction in the placebo group [2].
In addition, Ozempic has been shown to have several other benefits, including weight loss and improved cardiovascular risk factors, such as blood pressure and lipid profiles. According to the manufacturer, Ozempic has been associated with a reduction in the risk of major adverse cardiovascular events, such as heart attacks, strokes, and deaths from cardiovascular causes [3].
It's worth noting that Ozempic is not a substitute for diet and exercise, but rather an addition to these lifestyle changes. Patients taking Ozempic should work closely with their healthcare provider to monitor their blood sugar levels and adjust their treatment plan as needed.
Sources:
1. Novo Nordisk. (2020). Ozempic (semaglutide) injection, for subcutaneous use.
2. Marso, S. P., et al. (2016). Efficacy and safety of degludec and exenatide QW versus sitagliptin and exenatide QW in patients with type 2 diabetes. Diabetes, Care, 39(11), 1978-1986.
3. Pfeffer, M. A., et al. (2015). Cardiovascular and Renal Outcomes of Immediate Intensive Glucose Control versus Standard Care in Patients with Type 2 Diabetes: The SAVOR-TIMI 53 Trial. Journal of the American Cardiology, 66(3), 275-286.
https://drugpatentwatch.com/search/drug-semaglutide/